Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 2 weeks... Ophthalmic Drugs
News FDA approves Valeant eye drug after manufacturing delay Regulator backs potential blockbuster ophthalmology drug
Views & Analysis Learning from a successful ophthalmology brand launch Applying learnings from a successful ophthalmology brand launch to other therapy areas and pharmaceutical brands.
Partner Content Partner Content SMi’s Ophthalmic Drugs Conference is only 4 weeks away! Only 4 Weeks Remain for Ophthalmic Drugs
Partner Content Partner Content Spotlight on Key Sessions at Ophthalmic Drugs this November Sessions at Ophthalmic Drugs
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
